L, C., Q, W., & M, G. (2026). Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology, 16, 1732708. https://doi.org/10.3389/fendo.2025.1732708
Chicago Style (17th ed.) CitationL, Chen, Wang Q, and Gu M. "Assessment of the Efficacy and Safety of Anti-sclerostin Antibody Therapy for Osteoporosis in Postmenopausal Women: A Systematic Review and Meta-analysis of Randomized Controlled Trials." Frontiers in Endocrinology 16 (2026): 1732708. https://doi.org/10.3389/fendo.2025.1732708.
MLA (9th ed.) CitationL, Chen, et al. "Assessment of the Efficacy and Safety of Anti-sclerostin Antibody Therapy for Osteoporosis in Postmenopausal Women: A Systematic Review and Meta-analysis of Randomized Controlled Trials." Frontiers in Endocrinology, vol. 16, 2026, p. 1732708, https://doi.org/10.3389/fendo.2025.1732708.
